Diagnosis and Management of Vertebral Compression Fractures

 

Am Fam Physician. 2016 Jul 1;94(1):44-50.

Author disclosure: No relevant financial affiliations.

Vertebral compression fractures (VCFs) are the most common complication of osteoporosis, affecting more than 700,000 Americans annually. Fracture risk increases with age, with four in 10 white women older than 50 years experiencing a hip, spine, or vertebral fracture in their lifetime. VCFs can lead to chronic pain, disfigurement, height loss, impaired activities of daily living, increased risk of pressure sores, pneumonia, and psychological distress. Patients with an acute VCF may report abrupt onset of back pain with position changes, coughing, sneezing, or lifting. Physical examination findings are often normal, but can demonstrate kyphosis and midline spine tenderness. More than two-thirds of patients are asymptomatic and diagnosed incidentally on plain radiography. Acute VCFs may be treated with analgesics such as acetaminophen, nonsteroidal anti-inflammatory drugs, narcotics, and calcitonin. Physicians must be mindful of medication adverse effects in older patients. Other conservative therapeutic options include limited bed rest, bracing, physical therapy, nerve root blocks, and epidural injections. Percutaneous vertebral augmentation, including vertebroplasty and kyphoplasty, is controversial, but can be considered in patients with inadequate pain relief with nonsurgical care or when persistent pain substantially affects quality of life. Family physicians can help prevent vertebral fractures through management of risk factors and the treatment of osteoporosis.

Vertebral compression fractures (VCFs) are the most common complication of osteoporosis, affecting more than 700,000 Americans annually.1 Patients with VCFs account for 66,000 physician office visits and 45,000 to 70,000 hospitalizations each year, with one-half requiring skilled nursing facility care.2 Fracture risk increases with age; in the United States, four out of 10 white women older than 50 years will experience a hip, spine, or vertebral fracture in their lifetime.2 Women with one or more VCFs have a 1.2-fold greater age-adjusted mortality rate compared with women without fractures, with the risk of death increasing with the number of fractures.3 Fracture-related deaths occur after the fracture, often from pulmonary disease or cancer.3,4 Furthermore, patients report a lower quality of life at 12 and 24 months after a fracture.2 The estimated direct annual health care cost of managing osteoporotic spine and hip fractures is $10 billion to $15 billion.5

WHAT IS NEW ON THIS TOPIC: VERTEBRAL COMPRESSION FRACTURES

Two randomized controlled trials comparing vertebroplasty with a sham procedure in patients with acute or chronic vertebral compression fractures found no benefit in pain reduction, function, or quality of life.

Patients with vertebral compression fractures should not undergo vertebroplasty unless they continue to have debilitating pain or substantial functional limitations after at least three weeks of conservative therapy.

 Enlarge     Print

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

A trial of conservative therapy should be offered to patients with vertebral compression fractures.

C

13, 17, 18, 21

Percutaneous vertebral augmentation can be considered in patients who have inadequate pain relief with nonsurgical care or when persistent pain substantially affects quality of life.

C

13, 15, 17, 21

Patients with vertebral compression fractures should be evaluated for osteoporosis, and preventive therapy should be initiated if necessary.

C

6, 22, 41


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendationEvidence ratingReferences

A trial of conservative therapy should be offered to patients with vertebral compression fractures.

C

13, 17, 18, 21

Percutaneous vertebral augmentation can be considered in patients who have inadequate pain relief with nonsurgical care or when persistent pain substantially affects quality of life.

C

13, 15, 17, 21

Patients with vertebral compression fractures should be evaluated for osteoporosis, and preventive therapy should be initiated if necessary.

C

6, 22, 41


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.

Risk Factors

Risk factors for VCFs include osteopenia, osteoporosis, older age, a history of VCFs or falls, inactivity, use of corticosteroids (more than 5 mg daily for three months) or other medications, weight less than 117 lb (53.1 kg), female sex, consumption of more than two alcoholic drinks per day in women or more than three per day in men, smoking, vitamin D deficiency, and depression.69

Clinical Presentation

More than two-thirds of patients with VCFs are asymptomatic, and are diagnosed incidentally.10 Symptomatic patients may present with back pain and fracture demonstrated on radiography, most commonly between T8 and L4.11 Patients with an acute fracture may report abrupt onset of pain with position changes, coughing, sneezing, or lifting.8,12,13 Physical examination findings are often normal, but may demonstrate kyphosis and midline spine tenderness.8,12 Chronic VCF may present with loss of height in addition to kyphosis. Complications include bone loss, muscle weakness, pressure sores, ileus, urinary retention, impaired respiratory function, venous thromboembolism, and spinal cord compression.12,1417

The differential diagnosis includes musculoskeletal pain, osteoarthritis, spinal stenosis, multiple myeloma, metastatic disease, hyperparathyroidism, osteomalacia, primary bone neoplasms, infiltrative neoplasms, metastatic neoplasms, hematologic disease, trauma, and osteomyelitis.15,18

Evaluation

The physical examination should include a neurologic assessment. Compression fractures are typically diagnosed by lateral radiography of the vertebral column, with or without anteroposterior views.19 Radiographic criteria for VCFs include a decrease in vertebral body height of at least 20% or a 4-mm reduction from baseline height.14 The classic radiographic finding is an anterior wedge fracture8,12,19 (Figure 18).

 Enlarge     Print

Figure 1.

Wedge fracture.

Reprinted with permission from Old JL, Calvert M. Vertebral compression fractures in the elderly. Am Fam Physician. 2004;69(1):112.


Figure 1.

Wedge fracture.

Reprinted with permission from Old JL, Calvert M. Vertebral compression fractures in the elderly. Am Fam Physician. 2004;69(1):112.

Magnetic resonance imaging (MRI) can help distinguish benign from malignant fractures and determine the timing of the fracture, because recent fractures display edema.14,15 MRI or computed tomography is useful for identifying suspected retropulsion, fractures extending to the posterior column, and spinal cord involvement.14,15 Computed tomography or MRI should also be considered in patients who do not improve with conservative care and in those with progressive symptoms.8,14,15,17 Dual-energy x-ray absorptiometry should be performed soon after the diagnosis of a VCF to evaluate for osteoporosis and determine disease severity.6,14,15

If secondary osteoporosis is suspected (e.g., in a younger patient or in one with symptoms of hypercalcemia or anemia), laboratory evaluation may include a complete blood count; complete metabolic panel with liver function testing; and measurement of erythrocyte sedimentation rate and thyroid-stimulating hormone, 25-hydroxyvitamin D, parathyroid hormone, and C-reactive protein levels.6 Blood cultures are recommended when infection is suspected. Serum and urine protein electrophoresis should be performed if multiple myeloma is suspected. There is a high prevalence of low testosterone levels in younger men with osteoporosis and low-trauma fractures, and measurement of the testosterone level may be considered in these patients.20

Treatment

Goals of treatment include pain relief, restoration of function, and prevention of future fractures.12,14 Treatment of VCFs should begin with discussion of patient goals and risks, and benefits of conservative care vs. percutaneous vertebral augmentation. Patients who wish to pursue conservative treatment will have more than a 50% chance of sufficient pain reduction, most of which occurs by three months.21 A study of 259 patients with VCFs showed that patients who had pain relief and reduced disability with three weeks of conservative therapy had a 95% chance of maintaining these improvements for up to 12 months.21

CONSERVATIVE CARE

Early mobility should be encouraged as soon as it can be tolerated. Bed rest is sometimes recommended as part of initial management if pain is intolerable, but it can lead to loss of bone mass and muscle strength, pressure sores, and deep venous thrombosis.17 The American Academy of Orthopaedic Surgeons (AAOS) found inconclusive evidence regarding the benefits of bed rest in the treatment of VCFs.22

Medications. Nonsteroidal anti-inflammatory drugs, acetaminophen, narcotics, lidocaine patches, and muscle relaxants are commonly used for pain relief.7,8,12,14 Medications facilitate patient mobility and participation in physical therapy, and should be tapered slowly as pain improves.12 The AAOS found inconclusive evidence to support specific analgesics for acute VCF pain.22 In neurologically intact patients with VCF, calcitonin significantly reduces pain and facilitates earlier mobilization for up to four weeks.2225  Table 1 reviews common medications used to treat VCFs.26 Physicians should be mindful of medication adverse effects in older patients.

 Enlarge     Print

Table 1.

Medications for Acute Treatment of Vertebral Compression Fractures

MedicationDosageAdverse effectsCost*

Acetaminophen

500 to 1,000 mg every four to eight hours (maximum 3 g per day)

Analgesic-associated nephropathy (chronic), anemia, hepatotoxicity, hypersensitivity, renal tubular necrosis (acute), skin reactions, thrombocytopenia

$15

Calcitonin

200 IU per day intranasally

Anorexia, dizziness, flushing, gastrointestinal disturbance, headache, hypertension, hypocalcemia, rash, rhinitis (intranasal), weight gain

$45

Lidocaine 5% patch

Apply to affected area for 12 hours

Dermatitis, edema, exacerbation of pain, skin depigmentation, urticaria

$220

Muscle relaxants (e.g., cyclobenzaprine)

10 mg every eight hours

Abuse, anticholinergic effects, dependence, dizziness, sedation, serotonin syndrome when combined with other serotonergic medications

Varies

Narcotics (multiple brands)

Varies

Addiction, cognitive impairment, constipation, delirium, dizziness, hypogonadism, nausea, opioid-induced hyperalgesia, pruritus, respiratory depression, somnolence, urine retention

Varies

Nonsteroidal anti-inflammatory drugs

Ibuprofen

200 to 800 mg every eight hours

Atrial fibrillation, bleeding, cardiovascular disease, edema, gastritis, gastrointestinal bleeding, heart failure, hypertension, kidney disease, peptic ulcers

$11

Naproxen (Naprosyn)

500 mg every 12 hours

$4 ($186 for Naprosyn)


*—Estimated retail price for one month's treatment based on information obtained at http://www.goodrx.com and http://www.drugstore.com (accessed January 4, 2016).

Information from reference 26.

Table 1.

Medications for Acute Treatment of Vertebral Compression Fractures

MedicationDosageAdverse effectsCost*

Acetaminophen

500 to 1,000 mg every four to eight hours (maximum 3 g per day)

Analgesic-associated nephropathy (chronic), anemia, hepatotoxicity, hypersensitivity, renal tubular necrosis (acute), skin reactions, thrombocytopenia

$15

Calcitonin

200 IU per day intranasally

Anorexia, dizziness, flushing, gastrointestinal disturbance, headache, hypertension, hypocalcemia, rash, rhinitis (intranasal), weight gain

$45

Lidocaine 5% patch

Apply to affected area for 12 hours

Dermatitis, edema, exacerbation of pain, skin depigmentation, urticaria

$220

Muscle relaxants (e.g., cyclobenzaprine)

10 mg every eight hours

Abuse, anticholinergic effects, dependence, dizziness, sedation, serotonin syndrome when combined with other serotonergic medications

Varies

Narcotics (multiple brands)

Varies

Addiction, cognitive impairment, constipation, delirium, dizziness, hypogonadism, nausea, opioid-induced hyperalgesia, pruritus, respiratory depression, somnolence, urine retention

Varies

Nonsteroidal anti-inflammatory drugs

Ibuprofen

200 to 800 mg every eight hours

Atrial fibrillation, bleeding, cardiovascular disease, edema, gastritis, gastrointestinal bleeding, heart failure, hypertension, kidney disease, peptic ulcers

$11

Naproxen (Naprosyn)

500 mg every 12 hours

$4 ($186 for Naprosyn)


*—Estimated retail price for one month's treatment based on information obtained at http://www.goodrx.com and http://www.drugstore.com (accessed January 4, 2016).

Information from reference 26.

Bracing. Although bracing is commonly prescribed for six to eight weeks after a VCF, the evidence is limited.14,22 A small study of thoracolumbar bracing improved posture, strength, and quality of life.27 In another study, disability scores were not significantly improved in patients who wore a rigid brace or soft brace compared with those who did not wear a brace.28 Potential benefits of pain reduction should be balanced against the risks of muscle atrophy and skin complications.12,13

Physical Therapy and Exercise. Physical therapy is likely to be useful in patients with VCFs and osteoporosis.12,14,29 Home exercise programs have a more limited evidence base, with some small trials demonstrating pain reduction, improved balance, and quality of life.22,30 Back extensor strengthening can improve strength and bone density, and reduce the risk of future VCFs.31 Exercise is beneficial for all patients with osteoporosis.6

Nerve Root Blocks. The AAOS gives a weak recommendation for the use of L2 nerve blocks for temporary pain reduction in patients with VCFs.22 Patients undergoing L2 selective nerve blocks have reduced pain for up to two weeks, with effects dissipating by one month.22 Patients with radicular pain may benefit from nerve root blocks or epidural injections.14 Family physicians should counsel patients to weigh the benefits of temporary pain relief against the risks of the procedure.

VERTEBROPLASTY AND KYPHOPLASTY

Percutaneous vertebral augmentation, including vertebroplasty or kyphoplasty, can be considered in patients with inadequate pain relief from nonsurgical care, or when persistent pain substantially affects quality of life13,15,17,18,21; however, recent studies have questioned their effectiveness.3234 Vertebroplasty entails injecting liquid cement into a collapsed vertebral body through a needle inserted transpedicularly. Kyphoplasty involves percutaneously injecting a balloon into the vertebral body, inflating it to restore vertebral height, and injecting cement to reduce pain.15,17 Complications include extravasation of cement (more common with vertebroplasty), embolism, neurologic injury, bleeding, hematoma, infection, and an increased risk of VCFs at other levels.13,15,17

In 2010, the AAOS strongly recommended against vertebroplasty in neurologically intact patients with VCFs.22 Two randomized controlled trials comparing vertebroplasty with a sham procedure in patients with acute or chronic VCF found no benefit in pain reduction, function, or quality of life.32,33 In contrast, a 2013 meta-analysis of six randomized controlled trials (including those that found no benefits) found that vertebroplasty provided better pain relief, functionality, and quality of life compared with conservative care at 12 weeks, six months, and 12 months.35

Studies have demonstrated improved quality of life and physical abilities, and reduced back pain and disability in patients with kyphoplasty compared with conservative therapy at one month.22,36 Benefits in pain reduction and quality of life may persist for up to one year after kyphoplasty.

A 2014 consensus statement from several U.S. and Canadian neurosurgical and radiologic groups supports offering vertebroplasty and kyphoplasty to patients receiving medical therapy who are unable to ambulate after 24 hours of treatment, who have pain intense enough to prevent participation in physical therapy, or who have adverse effects from analgesics.17 Potential benefits must be evaluated against the failure of percutaneous vertebral augmentation to improve mortality or major medical outcomes and the increased health care utilization and complications associated with the procedures. Mortality benefits reported in studies of percutaneous vertebral augmentation may be linked to selection bias caused by the exclusion of patients at high risk of complications.34

Based on current evidence, most patients should not undergo percutaneous vertebral augmentation unless they present with acute MRI-confirmed fracture and debilitating pain or substantial functional limitations despite conservative therapy for at least three weeks.

Prevention

Optimal treatment of patients with VCFs includes prevention of additional fractures and treatment of osteoporosis. Family physicians can encourage weight-bearing and muscle-strengthening exercise, smoking cessation, and avoidance of excessive alcohol consumption; and assess the risk of falls.6

Screening for osteoporosis can identify patients who are most likely to benefit from treatment to reduce the likelihood of VCFs. The Institute of Medicine recommends adequate intake of calcium (1,000 mg per day for men 50 to 70 years of age, and 1,200 mg per day for women 51 years and older and men 71 years and older) and vitamin D (600 IU per day up to 70 years of age, 800 IU per day after 70 years of age).6,37 However, the U.S. Preventive Services Task Force found insufficient evidence to recommend more than 400 IU per day of supplemental vitamin D or more than 1,000 mg per day of calcium for primary prevention of fractures in non-institutionalized postmenopausal women, and they recommend against supplementation with lower amounts because of proven lack of benefit.38,39

Patients with VCFs have a fivefold increased risk of subsequent VCFs and a two- to threefold increased risk of fractures at other sites.6 Those with a hip fracture or VCF should be evaluated for osteoporosis. Patients with a T-score of −2.5 or lower at the femoral neck, total hip, or lumbar spine; a T-score of −1 to −2.4 at the femoral neck or lumbar spine; a 10-year probability of hip fracture of 3% or more; or a 10-year probability of a major osteoporosis-related fracture (clinical vertebral, hip, forearm, or proximal humerus fracture) of 20% or more should receive treatment.6

Medications approved by the U.S. Food and Drug Administration for the treatment and prevention of osteoporosis include bisphosphonates, calcitonin, estrogen, selective estrogen receptor modulators, parathyroid hormone, and receptor activator of nuclear factor kappa-B ligand inhibitors6  (Table 23,8,34,36,37,3941). Multiple bisphosphonates are approved for the primary and secondary prevention of VCFs.6,22,40,41 Although estrogen therapy has been approved for the prevention of osteoporosis, it should be considered only after nonestrogen treatments have been tried.6 The anabolic agent teriparatide (Forteo) reduces the risk of subsequent VCFs, although it is expensive and must be administered by daily subcutaneous injection.6,42 Additionally, denosumab (Prolia) leads to a relative decrease in new VCFs compared with placebo in postmenopausal women with osteoporosis. Denosumab can be used as an alternative to other therapies for the primary prevention of VCFs in postmenopausal women with osteoporosis.43

 Enlarge     Print

Table 2.

Medications for the Prevention and Treatment of Osteoporosis

MedicationDosageRelative risk reduction in vertebral fracturesMechanism of actionUsed for

Bisphosphonates

Antiresorptives; inhibit osteoclasts by inducing apoptosis

Prevention and treatment

Alendronate (Fosamax)

5 mg per day (prevention) or 35 mg per week (treatment)

50% in patients with history of fracture; 48% in those without

Ibandronate (Boniva)

150 mg per month

50%

Risedronate (Actonel)

5 mg per day or 35 mg per week

41% to 49%

Zoledronic acid (Reclast)

5 mg intravenously every two years (prevention) or 5 mg intravenously per year (treatment)

70%

Calcitonin

50 to 100 IU per day intramuscularly or 200 IU per day intranasally

30% in patients with history of fracture

Antiresorptive

Treatment

Calcium

1,000 to 1,200 mg per day

Prevention

Estrogen

0.3 mg or 0.625 mg per day via pill or patch

34%

Antiresorptive

Prevention

Estrogen agonist/antagonist (raloxifene [Evista])

60 mg per day

30% in patients with history of fracture; 55% in those without

Antiresorptive

Prevention and treatment

Parathyroid hormone (teriparatide [Forteo])

20 mcg per day subcutaneously for up to 24 months

65%

Maintains osteocytes, increases intestinal calcium absorption, decreases urinary calcium, increases vitamin D production

Treatment

RANKL inhibitor (denosumab [Prolia])

60 mg per day subcutaneously every six months

68%

Blocks formation, function, and survival of osteoclasts

Treatment

Vitamin D

800 to 1,000 IU per day

Prevention


RANKL = receptor activator of nuclear factor kappa-B ligand.

Information from references 3, 8, 34, 36, 37, and 39 through 41.

Table 2.

Medications for the Prevention and Treatment of Osteoporosis

MedicationDosageRelative risk reduction in vertebral fracturesMechanism of actionUsed for

Bisphosphonates

Antiresorptives; inhibit osteoclasts by inducing apoptosis

Prevention and treatment

Alendronate (Fosamax)

5 mg per day (prevention) or 35 mg per week (treatment)

50% in patients with history of fracture; 48% in those without

Ibandronate (Boniva)

150 mg per month

50%

Risedronate (Actonel)

5 mg per day or 35 mg per week

41% to 49%

Zoledronic acid (Reclast)

5 mg intravenously every two years (prevention) or 5 mg intravenously per year (treatment)

70%

Calcitonin

50 to 100 IU per day intramuscularly or 200 IU per day intranasally

30% in patients with history of fracture

Antiresorptive

Treatment

Calcium

1,000 to 1,200 mg per day

Prevention

Estrogen

0.3 mg or 0.625 mg per day via pill or patch

34%

Antiresorptive

Prevention

Estrogen agonist/antagonist (raloxifene [Evista])

60 mg per day

30% in patients with history of fracture; 55% in those without

Antiresorptive

Prevention and treatment

Parathyroid hormone (teriparatide [Forteo])

20 mcg per day subcutaneously for up to 24 months

65%

Maintains osteocytes, increases intestinal calcium absorption, decreases urinary calcium, increases vitamin D production

Treatment

RANKL inhibitor (denosumab [Prolia])

60 mg per day subcutaneously every six months

68%

Blocks formation, function, and survival of osteoclasts

Treatment

Vitamin D

800 to 1,000 IU per day

Prevention


RANKL = receptor activator of nuclear factor kappa-B ligand.

Information from references 3, 8, 34, 36, 37, and 39 through 41.

Data Sources: Medline and Essential Evidence Plus searches were completed using the following MeSH terms: fractures; fractures, compression; spinal cord compression; spinal fractures. MeSH subheadings included: drug therapy, prevention & control, rehabilitation, therapy. The following key words were used: vertebral compression fracture, conservative, nonoperative, nonsurgical. The search included randomized controlled trials, meta-analyses, clinical trials, systematic reviews, clinical practice guidelines, evidence-based medicine, and review articles. Search dates: January 1996 through December 2014.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Air Force or the Department of Defense.

The Authors

show all author info

JASON McCARTHY, MD, is a faculty physician at the David Grant Medical Center Family Medicine Residency Program, Travis Air Force Base, Calif....

AMY DAVIS, MD, is a faculty physician at the David Grant Medical Center Family Medicine Residency Program.

The authors thank Pamela M. Williams, MD; Kathy Holder, MD; and Regina Rowell for their assistance with the manuscript.

Author disclosure: No relevant financial affiliations.

Address correspondence to Jason McCarthy, MD, David Grant Medical Center, 101 Bodin Cir., Travis Air Force Base, CA 94535 (e-mail: jason.mccarthy.6@us.af.mil). Reprints are not available from the authors.

REFERENCES

show all references

1. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17(5 suppl):505S–511S....

2. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, Md.: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004:1–404.

3. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR; Study of Osteoporotic Fractures Research Group. Vertebral fractures and mortality in older women: a prospective study. Arch Intern Med. 1999;159(11):1215–1220.

4. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003;18(6):1139–1141.

5. Marwick C. Consensus panel considers osteoporosis. JAMA. 2000;283(16):2093–2095.

6. Cosman F, de Beur SJ, LeBoff MS, et al.; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [published correction appears in Osteoporosis Int. 2015;26(7):2045–2047]. Osteoporos Int. 2014;25(10):2359–2381.

7. Ensrud KE, Schousboe JT. Clinical practice. Vertebral fractures. N Engl J Med. 2011;364(17):1634–1642.

8. Old JL, Calvert M. Vertebral compression fractures in the elderly. Am Fam Physician. 2004;69(1):111–116.

9. Whooley MA, Kip KE, Cauley JA, Ensrud KE, Nevitt MC, Browner WS; Study of Osteoporotic Fractures Research Group. Depression, falls, and risk of fracture in older women. Arch Intern Med. 1999;159(5):484–490.

10. Fink HA, Milavetz DL, Palermo L, et al.; Fracture Intervention Trial Research Group. What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res. 2005;20(7):1216–1222.

11. Patel U, Skingle S, Campbell GA, Crisp AJ, Boyle IT. Clinical profile of acute vertebral compression fractures in osteoporosis. Br J Rheumatol. 1991;30(6):418–421.

12. Longo UG, Loppini M, Denaro L, Maffulli N, Denaro V. Osteoporotic vertebral fractures: current concepts of conservative care. Br Med Bull. 2012;102:171–189.

13. Savage JW, Schroeder GD, Anderson PA. Vertebroplasty and kyphoplasty for the treatment of osteoporotic vertebral compression fractures. J Am Acad Orthop Surg. 2014;22(10):653–664.

14. Prather H, Hunt D, Watson JO, Gilula LA. Conservative care for patients with osteoporotic vertebral compression fractures. Phys Med Rehabil Clin N Am. 2007;18(3):577–591, xi.

15. McConnell CT Jr, Wippold FJ II, Ray CE Jr, et al. ACR appropriateness criteria management of vertebral compression fractures. J Am Coll Radiol. 2014;11(8):757–763.

16. Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am. 2014;98(4):817–831, xii–xiii.

17. Barr JD, Jensen ME, Hirsch JA, et al. Position statement on percutaneous vertebral augmentation: a consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS). J Vasc Interv Radiol. 2014;25(2):171–181.

18. Venmans A, Lohle PN, van Rooij WJ. Pain course in conservatively treated patients with back pain and a VCF on the spine radiograph (VERTOS III). Skeletal Radiol. 2014;43(1):13–18.

19. Kiel D; National Osteoporosis Foundation Working Group on Vertebral Fractures. Assessing vertebral fractures [published correction appears in J Bone Miner Res. 1995;10(10):1605]. J Bone Miner Res. 1995;10(4):518–523.

20. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559.

21. Lee HM, Park SY, Lee SH, Suh SW, Hong JY. Comparative analysis of clinical outcomes in patients with osteoporotic vertebral compression fractures (OVCFs): conservative treatment versus balloon kyphoplasty. Spine J. 2012;12(11):998–1005.

22. Esses SI, McGuire R, Jenkins J, et al. The treatment of symptomatic osteoporotic spinal compression fractures. J Am Acad Orthop Surg. 2011;19(3):176–182.

23. Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain. 1999;15(4):284–289.

24. Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int. 2005;16(10):1281–1290.

25. Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl. 1997;275:112–114.

26. Lexicomp Online. http://online.lexi.com [subscription required]. Accessed March 30, 2015.

27. Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil. 2004;83(3):177–186.

28. Kim HJ, Yi JM, Cho HG, et al. Comparative study of the treatment outcomes of osteoporotic compression fractures without neurologic injury using a rigid brace, a soft brace, and no brace: a prospective randomized controlled non-inferiority trial. J Bone Joint Surg Am. 2014;96(23):1959–1966.

29. Dusdal K, Grundmanis J, Luttin K, et al. Effects of therapeutic exercise for persons with osteoporotic vertebral fractures: a systematic review. Osteoporos Int. 2011;22(3):755–769.

30. Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int. 2003;14(8):677–682.

31. Sinaki M, Itoi E, Wahner HW, et al. Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women. Bone. 2002;30(6):836–841.

32. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361(6):557–568.

33. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures [published correction appears in N Engl J Med. 2012;366(10):970]. N Engl J Med. 2009;361(6):569–579.

34. McCullough BJ, Comstock BA, Deyo RA, Kreuter W, Jarvik JG. Major medical outcomes with spinal augmentation vs conservative therapy. JAMA Intern Med. 2013;173(16):1514–1521.

35. Anderson PA, Froyshteter AB, Tontz WL Jr. Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures. J Bone Miner Res. 2013;28(2):372–382.

36. Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009;373(9668):1016–1024.

37. Institute of Medicine. Dietary Reference Intakes: Calcium, Vitamin D. Washington, DC: National Academies Press; 2011.

38. Chung M, Balk EM, Brendel M, et al. Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep). 2009;(183):1–420.

39. U.S. Preventive Services Task Force. Final recommendation statement: vitamin D and calcium to prevent fractures: preventive medication, February 2013. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/vitamin-d-and-calcium-to-prevent-fractures-preventive-medication. Accessed February 6, 2015.

40. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD001155.

41. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1):CD004523.

42. Cranney A, Papaioannou A, Zytaruk N, et al.; Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ. 2006;175(1):52–59.

43. Cummings SR, San Martin J, McClung MR, et al.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [published correction appears in N Engl J Med. 2009;361(19):1914]. N Engl J Med. 2009;361(8):756–765.

 

 

Copyright © 2016 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Sep 15, 2017

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article